{"filing":{"accession_number":"0001193125-26-296398","cik":"0001811063","ticker":"NUVB","company_name":"Nuvation Bio Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"d136399d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526296398/d136399d8k.htm"},"events":[{"id":16251,"run_id":14502,"accession_number":"0001193125-26-296398","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Nuvation Bio completed a registered public offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including the full exercise of a $37.5 million greenshoe over-allotment option on July 6, 2026, generating net proceeds of approximately $277.6 million after underwriting costs.","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14295,"accession_number":"0001193125-26-296398","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Nuvation Bio completed a registered public offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including the full exercise of a $37.5 million greenshoe over-allotment option on July 6, 2026. This is a clear creation of a direct financial obligation—a new debt instrument with specified interest rate, maturity date, and conversion terms. The filing explicitly discloses the issuance under Item 2.03, the net proceeds ($277.6 million after underwriting costs), and the material terms of the indenture governing the Notes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:59:55.017617+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14296,"accession_number":"0001193125-26-296398","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing announces the full exercise of a Greenshoe option resulting in an additional $37.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, bringing the total offering to $287.5 million. This represents the creation of a new direct financial obligation through debt issuance. While the notes are convertible (equity-linked), the primary event is the issuance of debt securities, and the company explicitly discloses net proceeds of approximately $277.6 million after underwriting costs, which is material to investors assessing the registrant's capital structure and liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:59:55.017617+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14295,"accession_number":"0001193125-26-296398","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Nuvation Bio completed a registered public offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including the full exercise of a $37.5 million greenshoe over-allotment option on July 6, 2026. This is a clear creation of a direct financial obligation—a new debt instrument with specified interest rate, maturity date, and conversion terms. The filing explicitly discloses the issuance under Item 2.03, the net proceeds ($277.6 million after underwriting costs), and the material terms of the indenture governing the Notes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:59:55.017617+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-07-06"},{"id":14296,"accession_number":"0001193125-26-296398","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing announces the full exercise of a Greenshoe option resulting in an additional $37.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, bringing the total offering to $287.5 million. This represents the creation of a new direct financial obligation through debt issuance. While the notes are convertible (equity-linked), the primary event is the issuance of debt securities, and the company explicitly discloses net proceeds of approximately $277.6 million after underwriting costs, which is material to investors assessing the registrant's capital structure and liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:59:55.017617+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-07-06"}]}